06/01/23 8:00 AMNYSE : GSK GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the USGSK plc today announced the launch of the COiMMUNITY Initiative to help reduce health inequities and set a new precedent for adult immunization rates in the US, which continue to remain below pre-pandemic levels i. The initiative is a multipronged effort to address long-standing barriers to adult immunization in the US with funding, increased data...RHEA-AIneutral
05/16/23 5:01 PMNasdaq, NYSE : BLU, GSK acquisitionBELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK AcquisitionBELLUS Health Inc. today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting of shareholders of BELLUS on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution approving the previously-announced...RHEA-AIneutral
05/12/23 4:01 PMNasdaq, NYSE : BLU, GSK earningsBELLUS Health Reports First Quarter 2023 Financial Results and Business HighlightsBELLUS Health Inc., a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant for the treatment of refractory chronic cough, today reported its financial and operating results for the quarter ended March 31, 2023.. “Our merger agreement with GSK...RHEA-AIneutral
05/03/23 1:37 PMNYSE : GSK fda approvalUS FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older AdultsGSK plc today announced that the US Food and Drug Administration has approved AREXVY for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. This is the first RSV vaccine for older adults to be approved anywhere in the world. This press release features multimedia.RHEA-AIneutral
05/02/23 4:01 PMNasdaq, NYSE : ARWR, TAK, GSK Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter ResultsArrowhead Pharmaceuticals, Inc. today announced financial results for its fiscal second quarter ended March 31, 2023. The company is hosting a conference call today, May 2, 2023, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details.RHEA-AIneutral
04/18/23 12:11 PMNasdaq, NYSE : BLU, GSK acquisitionGSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS HealthGSK plc and BELLUS Health Inc. today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada- based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough for US $14.75 per share of common stock in cash representing an approximate total equity value of US...RHEA-AIneutral
04/03/23 7:30 AMNasdaq, NYSE : ARWR, GSK Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSKArrowhead Pharmaceuticals Inc. today announced that it earned a $30 million milestone payment from GSK following the start of GSK’ s Phase 2 b trial of GSK4532990, formerly called ARO-HSD, an investigational RNA interference therapeutic for the treatment of patients with non-alcoholic steatohepatitis. GSK received an exclusive license to develop and...RHEA-AIneutral
03/30/23 10:00 AMNYSE : GSK clinical trialPathAI Announces Collaboration with GSK on NASH Phase 2b Clinical TrialPathAI, a leading provider of AI-powered pathology, today announced its partnership with GSK on HORIZON, a randomized Phase 2 b non-alcoholic steatohepatitis clinical trial. The trial will measure improvements in liver histology with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis. This trial will utilize PathAI's full...RHEA-AIvery positive
03/27/23 6:21 PMNYSE : GSK clinical trialPhase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy aloneGSK plc today announced interim results from Part 1 of the RUBY/ENGOT-EN-6-NSGO/GOG3031 phase III trial investigating Jemperli plus standard-of-care chemotherapy followed by dostarlimab-gxly compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. Hesham Abdullah, Senior...RHEA-AIneutral
03/14/23 12:00 PMNYSE : GSK partnershipGSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older AdultsGSK plc has partnered with Earvin“ Magic” Johnson to launch Sideline RSV, a new health education campaign aimed to help older adults and their loved ones better understand the risks and potential seriousness of RSV infection and how to help protect themselves. This press release features multimedia. View the full release here:...RHEA-AIneutral
